Shukra Pharma rescheduled its 33rd Annual General Meeting due to administrative reasons. Book closure dates for the AGM are also revised. All previously announced agenda items and appointments remain unchanged.
Shukra Pharmaceuticals announced a ₹0.01 per share final dividend for FY25-26, pending shareholder approval at the upcoming AGM. A record date is established to determine eligible shareholders.
Shukra Pharmaceuticals is now listed on both BSE and NSE. Company is focusing on medical technology, AI, and innovation for future growth and diversification.
Shukra Pharmaceuticals has announced a board meeting to consider a name change to "Shukra Medtech Limited" and expand its business into Medical Technology (MedTech). This strategic move aims to broaden the company's scope and explore new growth opportunities.
Shukra Pharmaceuticals enters a strategic joint venture with Borns Medical Robotics to design, manufacture, and service AI-enabled surgical robots in India and APAC. Shukra will hold 60% stake.
